Prospectus Breakdown: How to Read Every Section from Cover to Risk Factors

The HKEX’s Listing Reform Package of 2025, which introduced Chapter 18C for specialist technology companies and streamlined Chapter 8A for weighted voting rights (WVR) structures, has fundamentally altered the informational burden on prospectuses. With the SFC’s enhanced disclosure requirements under the Code of Conduct for Sponsors (effective 1 January 2026), sponsors must now include granular data on pre-IPO investments, intellectual property valuations, and revenue recognition triggers in the “Summary” and “Risk Factors” sections. This shift means that a prospectus is no longer a static compliance document but a dynamic, investor-facing data repository. For IPO analysts and institutional investors, the ability to decode each section—from the cover’s listing date to the risk factors’ probability-weighted loss scenarios—is now a prerequisite for accurate valuation and regulatory scrutiny. This breakdown provides a section-by-section guide to reading a HKEX Main Board prospectus, referencing the specific rules and market mechanics that govern each component.

The Cover, Summary, and Key Statistics: The First 30 Seconds

The cover page and summary section are the most heavily regulated parts of a prospectus under the HKEX Listing Rules, Appendix 1A, Part A. They must contain specific statutory disclosures, including the exact listing date, the sponsor’s name, the global coordinator’s role, and the minimum subscription amount. For a 2026 IPO, the cover will also display the HKEX’s new “Specialist Technology Company” badge if the issuer falls under Chapter 18C, which requires a minimum market capitalisation of HKD 8 billion at listing.

Reading the Cover: Jurisdiction, Sponsor, and Listing Date

The cover must state the issuer’s jurisdiction of incorporation—most commonly the Cayman Islands, Bermuda, or Hong Kong. For PRC-based issuers using a VIE structure, the cover will include a prominent warning that “The company is not a PRC operating company but a Cayman Islands holding company with contractual arrangements with PRC entities.” This language is mandated by SFC’s Guidance Note on VIE Structures (2023). The listing date is the single most important data point for aftermarket liquidity; a Friday listing often correlates with higher first-day volatility due to fewer institutional orders. The sponsor’s name—typically a bulge-bracket bank like Goldman Sachs, Morgan Stanley, or a Chinese house like CITIC—indicates the underwriting syndicate’s quality. A single sponsor signals a smaller deal; a joint global coordinator team of three or more suggests a large cap above HKD 10 billion.

The Summary: The 5-Page Thesis

The summary section, limited to approximately five pages under HKEX Listing Rule 11.07, must contain the “Investment Highlights” and “Key Financials.” The Investment Highlights are the sponsor’s narrative—not the issuer’s. Experienced analysts cross-reference these claims against the “Risk Factors” section. For example, if the summary claims “industry-leading gross margins of 65%,” the risk factors should disclose that “gross margins may decline due to raw material price volatility.” The Key Financials table must show three fiscal years of revenue, gross profit, net income, and adjusted net income. Under the 2025 Listing Reform, adjusted net income must be reconciled to IFRS or HKFRS net income in a footnote, with adjustments for share-based compensation, IPO expenses, and non-recurring items. For Chapter 18C issuers, the summary must also include a “Key Operating Metrics” table—such as monthly active users (MAU) for a tech platform or total contract value (TCV) for a SaaS company—audited by the reporting accountant.

Key Statistics: Price, Market Cap, and Free Float

The “Key Statistics” box on the cover or summary page provides the offer price range, the implied market capitalisation at the midpoint, and the free float percentage. The HKEX requires a minimum free float of 25% for Main Board listings (Listing Rule 8.08), or 15% for issuers with a market cap above HKD 10 billion. For a 2026 IPO, the free float is critical for index inclusion; a free float below 15% will disqualify the stock from the Hang Seng Index. The offer price range is typically 10-15% wide—for example, HKD 88.00 to HKD 100.00 per share. The midpoint is used for cornerstone investor allocations and the stabilisation period. The number of shares offered, including the 15% overallotment option (greenshoe), determines the total deal size. For a HKD 10 billion IPO, the greenshoe is HKD 1.5 billion, exercisable by the sole global coordinator within 30 days of listing.

The Industry Overview and Business Sections: The Operating Thesis

These sections, typically 30-50 pages, are the narrative backbone of the prospectus. They must comply with SFC’s Code of Conduct for Sponsors, Paragraph 17, which requires sponsors to verify all market data and industry forecasts against independent third-party sources. The HKEX Listing Decision HKEX-LD127-2024 further clarified that industry reports commissioned from third-party consultants (e.g., Frost & Sullivan, Euromonitor) must disclose the consultant’s methodology, sample size, and any conflicts of interest.

Industry Overview: Market Size, Growth, and Competitive Positioning

The industry overview must present the total addressable market (TAM) in HKD or USD, with a compound annual growth rate (CAGR) over a five- to ten-year forecast period. For a 2026 IPO, a credible TAM for a Chinese biotech firm might be “USD 45.2 billion by 2030, growing at a CAGR of 12.3% (Frost & Sullivan, 2025).” The section must also include a competitive landscape table showing the issuer’s market share, typically ranked by revenue or units sold. For a fintech issuer, the market share might be “3.2% of the PRC digital payments market by transaction value (People’s Bank of China, 2024).” Analysts should verify these figures against publicly available data; if the issuer claims a top-three market position but the industry report only lists five competitors, the claim is likely inflated.

Business: Revenue Model, Customer Concentration, and Supply Chain

The business section describes the issuer’s revenue model—product sales, subscription fees, licensing, or platform commissions. Under HKEX Listing Rule 11.08, the prospectus must disclose the top five customers and their revenue contribution. For a manufacturing issuer, customer concentration above 50% from a single customer is a material risk. The supply chain section must list the top three suppliers and their geographic locations. For a semiconductor issuer, a dependency on a single Taiwanese foundry for 80% of wafer supply would trigger a risk factor under “Geopolitical and Trade Risks.” The section also includes intellectual property (IP) details: patents granted, patents pending, and trademark registrations. Under the SFC’s 2025 Guidance on IP Valuation, sponsors must verify that the issuer owns the IP outright and that no third-party claims exist. For a biotech issuer, the patent expiration dates are critical; a key patent expiring in 2028 would reduce the issuer’s competitive moat.

The Risk Factors Section: The Sponsor’s Liability Shield

The risk factors section is the longest and most legally dense part of the prospectus, often running 40-60 pages. Under the SFC’s Code of Conduct for Sponsors, Paragraph 15, sponsors must ensure that all material risks are disclosed in a “clear, concise, and understandable manner.” The HKEX Listing Decision HKEX-LD105-2023 established that risk factors must be specific to the issuer and its industry, not generic boilerplate. A generic statement like “the issuer faces competition” is insufficient; the risk must quantify the competitive threat, e.g., “the issuer’s top competitor, Company X, has a 40% market share and is expected to launch a competing product in Q3 2026.”

Business and Operational Risks

This sub-section covers risks specific to the issuer’s operations: customer concentration, supplier dependency, technology obsolescence, and key personnel dependency. For a Chapter 18C issuer, the risk factors must include “Uncertainty of Commercialisation” and “Dependence on a Single Product or Platform.” A typical risk factor reads: “The issuer’s revenue is derived primarily from its flagship product, Product A, which contributed 78.2% of total revenue for the fiscal year ended 31 December 2025. Any decline in demand for Product A would materially and adversely affect the issuer’s financial condition.” For a PRC-based issuer, business risks also include “Regulatory Risks Related to VIE Structures” and “PRC Data Security and Cross-Border Data Transfer Risks” under the PRC Personal Information Protection Law (PIPL) and the Data Security Law, both effective 2021.

Financial and Market Risks

Financial risks include currency fluctuation, interest rate exposure, and the impact of inflation on input costs. For a USD-denominated issuer with PRC revenue, the risk factor must disclose the impact of RMB depreciation: “A 10% depreciation of the RMB against the USD would reduce the issuer’s reported revenue by approximately HKD 150 million, based on the issuer’s 2025 revenue of HKD 1.5 billion.” Market risks include the volatility of the issuer’s stock price post-IPO, the lock-up period for pre-IPO investors (typically 6-12 months under HKEX Listing Rule 10.07), and the potential for short-selling. For a high-growth tech issuer, the risk factor must also disclose the “Impact of Rising Interest Rates on Valuation Multiples,” referencing the HKMA’s Base Rate changes.

Legal and Regulatory Risks

This sub-section covers specific legal proceedings, regulatory investigations, and changes in law. For a PRC issuer, the risk factors must disclose the “CSRC Filing Requirement” under the PRC Securities Law (2019) and the “Overseas Listing Rules” (effective 2023). The risk factor must state: “The issuer has completed the CSRC filing process on [date], but there can be no assurance that the CSRC will not require additional filings or impose restrictions on the issuer’s ability to raise capital or distribute dividends.” For a Hong Kong-incorporated issuer, the risk factor must reference the “HKEX Listing Rules and SFC Codes” and the potential for delisting if the issuer fails to maintain compliance.

The Use of Proceeds, Financials, and Statutory Disclosures

These sections provide the quantitative foundation for the investment thesis. The financials must be audited by a PCAOB-registered auditor for US-listed issuers or a HKICPA-registered auditor for Hong Kong-listed issuers. The use of proceeds section must be specific, with a breakdown by percentage and a timeline.

Use of Proceeds: The Allocation Formula

Under HKEX Listing Rule 11.10, the use of proceeds must be disclosed in a table showing the percentage allocated to each category: expansion, R&D, working capital, and debt repayment. For a 2026 IPO, a typical allocation might be: “Approximately 45% (HKD 4.5 billion) for expansion of production capacity in the PRC and Southeast Asia; 30% (HKD 3.0 billion) for research and development of new products; 15% (HKD 1.5 billion) for working capital and general corporate purposes; and 10% (HKD 1.0 billion) for repayment of bank loans.” The prospectus must also disclose the expected timeline for deployment—usually 12-24 months post-listing. For a biotech issuer, the R&D allocation must specify the clinical trial phases and expected completion dates.

Financial Statements: The Three-Statement Model

The financial statements must include the audited balance sheet, income statement, cash flow statement, and statement of changes in equity for the three most recent fiscal years. Under HKFRS 16, operating leases must be capitalised on the balance sheet, which can significantly increase reported debt. For a retail issuer with large store portfolios, the lease liability might represent 20-30% of total liabilities. The income statement must show gross profit, operating profit, and net profit, with a reconciliation to adjusted net profit. The cash flow statement must separate operating, investing, and financing activities. For a Chapter 18C issuer, the cash flow statement must also disclose “Cash Used in R&D Activities” as a separate line item. The notes to the financial statements provide granular detail on revenue recognition policies, share-based compensation, and contingent liabilities.

Statutory and General Information

This section includes the issuer’s constitutional documents, directors’ biographies, and the sponsor’s declaration. Under HKEX Listing Rule 11.13, the prospectus must include a “Statement of Directors’ Responsibilities” confirming that the prospectus complies with the Listing Rules and that there are no material omissions. The directors’ biographies must disclose their age, education, professional qualifications, and directorships in other listed companies. For a PRC issuer, the biographies must also disclose any “Party Committee” roles or “State-owned Enterprise” affiliations. The sponsor’s declaration, required under the SFC’s Code of Conduct, states that the sponsor has conducted reasonable due diligence and that the prospectus is accurate and complete. This declaration is a legal document; a false declaration can result in the sponsor’s licence being revoked.

Actionable Takeaways

• Cross-reference the “Investment Highlights” with the “Risk Factors” section: Any claim in the summary that is not substantiated by a corresponding risk factor is a red flag for sponsor due diligence gaps.
• Verify the free float percentage against the HKEX’s minimum of 25% (or 15% for large caps): A free float below 15% will exclude the stock from the Hang Seng Index and reduce institutional demand.
• Audit the use of proceeds timeline: If the issuer plans to deploy 45% of proceeds within 12 months but has no signed contracts or capital expenditure commitments, the risk of cash hoarding is high.
• Check the sponsor’s track record on prior IPOs: A sponsor with a high rate of post-IPO profit warnings or accounting restatements signals weak due diligence standards.
• Read the risk factors for probability-weighted loss scenarios: The SFC’s 2025 Guidance requires sponsors to quantify the financial impact of each material risk, not just list them generically.